Zimbabwe
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2012 14 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.6 (0.16–16) 33 (1.2–117)
Mortality (HIV+TB only) 18 (15–20) 132 (111–147)
Prevalence  (includes HIV+TB) 59 (13–140) 433 (92–1 034)
Incidence  (includes HIV+TB) 77 (60–97) 562 (434–706)
Incidence (HIV+TB only) 55 (42–69) 399 (308–501)
Case detection, all forms (%) 46 (37–60)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 12 163 (35) Relapse 1 369 (32)
Smear-negative 14 354 (42) Treatment after failure 200 (5)
Smear-unknown / not done 2 962 (9) Treatment after default 176 (4)
Extrapulmonary 4 912 (14) Other 2 584 (60)
Other 0 (0)      
Total new 34 391   Total retreatment 4 329  
           
Other (history unknown) 0        
Total new and relapse 35 760   Total cases notified 38 720  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.3 1.2 1.1
Age < 15 293 2 177 441
Laboratories 2012
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 81   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 80  
Retreatment 78  
TB/HIV 2012 Number (%)
TB patients with known HIV status 34 212 (88)
HIV-positive TB patients 23 957 (70)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 6 301 (26)
HIV-positive TB patients on antiretroviral therapy (ART) 4 419 (18)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.9 (1–3.3) 8.3 (1.8–22)
MDR-TB cases among notified pulmonary
TB cases
570 (300–960) 360 (76–970)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 360 (3%) 258 (6%) 689
Laboratory-confirmed MDR-TB cases 43 35 149
Patients started on MDR-TB treatment     105
Financing TB control 2013
National TB programme budget (US$ millions) 38
% Funded domestically 4%
% Funded internationally 39%
% Unfunded 56%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-17 Data: www.who.int/tb/data